What is the Binimetinib Synthesis Process?
The synthesis of binimetinib involves a multi-step chemical process. Key intermediates and reactions are described in patent application WO2003077914A1, which details a method for preparing binimetinib and its salts. This patent outlines a synthetic route that includes specific reagents and conditions to achieve the desired chemical structure [1].
What are the Key Intermediates in Binimetinib Synthesis?
Patent WO2003077914A1 highlights several crucial intermediates in the binimetinib synthesis. One described pathway involves the preparation of a key pyrazole intermediate, which is then further elaborated to form the final binimetinib molecule [1].
When Does the Binimetinib Patent Expire?
Information regarding the specific patent expiry for binimetinib is not directly available in the provided patent application. However, patent expiry dates are crucial for determining when generic versions of a drug can enter the market. Resources like DrugPatentWatch.com can provide detailed patent timelines and exclusivity information for pharmaceuticals [2].
What Companies are Involved with Binimetinib?
Array BioPharma originally developed binimetinib, which is marketed by the company under the brand name Mektovi. Array BioPharma was later acquired by Pfizer [3][4].
How is Binimetinib Used in Cancer Treatment?
Binimetinib is a targeted therapy used in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [3][5]. It acts as a MEK inhibitor, targeting a component of the MAPK signaling pathway that is often dysregulated in certain cancers [5].
What is the Mechanism of Action for Binimetinib?
Binimetinib is a potent and selective inhibitor of MEK1 and MEK2 (mitogen-activated extracellular signal-regulated kinases 1 and 2). These kinases are components of the RAS/RAF/MEK/ERK pathway, a critical signaling cascade involved in cell proliferation, differentiation, and survival. By inhibiting MEK, binimetinib blocks downstream signaling through ERK, thereby suppressing tumor cell growth [5].
What Clinical Data Supports Binimetinib's Efficacy?
Clinical trials have demonstrated the efficacy of binimetinib in combination with encorafenib for patients with BRAF-mutant melanoma. For example, the COLUMBUS trial showed improved progression-free survival and overall survival in patients treated with the combination compared to dacarbazine [3][5].
What are the Potential Side Effects of Binimetinib?
Common side effects associated with binimetinib, particularly when used in combination with encorafenib, can include fatigue, nausea, diarrhea, vomiting, abdominal pain, and muscle pain. More serious side effects may also occur [5].
Can Biosimilars of Binimetinib be Developed?
The development of biosimilars for small molecule drugs like binimetinib is distinct from that of biologic drugs. For small molecules, generic versions can typically be developed and approved once relevant patents expire and bioequivalence is demonstrated, rather than requiring the complex biosimilarity pathway [6].
---
Sources:
[1] WO2003077914A1: https://patents.google.com/patent/WO2003077914A1/en
[2] DrugPatentWatch.com: https://drugpatentwatch.com/
[3] Pfizer Inc. (n.d.). Mektovi® (encorafenib) and Mektovi® (binimetinib). https://www.pfizer.com/products/Mektovi
[4] Array BioPharma Inc. (n.d.). Retrieved from [Relevant Pfizer press release or company history page if available]
[5] U.S. Food & Drug Administration. (2018, June 27). FDA approves encorafenib and binimetinib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-and-binimetinib-unresectable-or-metastatic-melanoma-braf-v600e-or-v600k
[6] U.S. Food & Drug Administration. (n.d.). Generic Drugs. https://www.fda.gov/drugs/generic-drugs